Students Research in Progress
Sunday, November 12, 2023
12:45 PM–02:15 PM
Abstract
Introduction:
Heart failure with reduced ejection fraction (HFrEF) can lead to decreased iron absorption, increased inflammation, and blood loss. According to the American Heart Association (AHA), patients with HFrEF and iron deficiency with or without anemia may benefit from intravenous iron replacement. Intravenous iron can improve exercise capacity and quality of life. The FAIR-HF trial showed improvement in NYHA classification, 6-minute walk test, and quality of life in outpatients with chronic HF who were given weekly ferric carboxymaltose infusions until iron was repleted. The IRONOUT HF trial showed no improvement with the supplementation of oral iron; therefore, the AHA guidelines suggest oral iron is not adequate to treat iron deficiency anemia. There is no consensus on specific dosing or monitoring regimens in heart failure.
Research Question or Hypothesis:
In patients with documented heart failure, what are the current prescribing and monitoring practices for intravenous iron sucrose and are there opportunities for optimization at Nebraska Medicine?
Study Design: Retrospective Chart Review
Methods:
A retrospective chart review was conducted to assess prescribing patterns of intravenous iron in hospitalized adult patients with a diagnosis of heart failure during calendar years 2021 and 2022. Data were pulled from the electronic health record by ICD-10 code for heart failure and administration of intravenous iron sucrose during hospitalization. After removing duplicate records, every fifth patient was chart reviewed for a target sample of 75. Data points collected included baseline characteristics, heart failure diagnosis, ejection fraction, and pertinent labs. Inclusion criteria were adult patients aged 19 years or older, history of documented heart failure, documented echocardiogram, and intravenous iron sucrose administration during hospital admission. Patients were excluded if they did not receive intravenous iron sucrose during admission, age less than 19 years old, no history of heart failure, or no echocardiogram on their profile. Descriptive statistics will be utilized to evaluate data.
Results: In-progress
Conclusion: In-progress
Presenting Author
Adam Roskam PharmD CandidateUniversity of Nebraska Medical Center
Authors
Molly Kernan PharmD
Nebraska Medicine
Sara Kjerengtroen PharmD, BCPS
Nebraska Medicine
Tuesday Neary PharmD, BCPS
Nebraska Medicine
Jenel Proksel PharmD, BCPS
Nebraska Medicine
Shawna Stricker PharmD
Nebraska Medicine